Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 31% Improvement Relative Risk Mortality/ICU/cardiovasc.. 44% primary ICU admission 14% Hospitalization time 9% Time to viral- 62% Viral clearance 73% c19early.org/pl Yan et al. Paxlovid for COVID-19 EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Retrospective 195 patients in China (April - June 2022) Lower progression (p=0.038) and shorter hospitalization (p=0.026) Yan et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980 Favors paxlovid Favors control
Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
Yan et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980
Yan et al., Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron.., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 195 patients with impaired kidney function in China, showing lower combined mortality/ICU/cardiovascular events, and improved viral clearance with paxlovid.
Confounding by contraindication. [Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
risk of death, 31.2% lower, RR 0.69, p = 0.50, treatment 7 of 73 (9.6%), control 17 of 122 (13.9%), NNT 23.
mortality/ICU/cardiovascular events, 44.0% lower, HR 0.56, p = 0.04, treatment 73, control 122, adjusted per study, multivariable, model 2, primary outcome.
risk of ICU admission, 13.9% lower, RR 0.86, p = 0.61, treatment 17 of 73 (23.3%), control 33 of 122 (27.0%), NNT 27.
hospitalization time, 8.6% lower, relative time 0.91, p = 0.03, treatment 73, control 122.
time to viral-, 61.5% lower, relative time 0.38, p = 0.001, treatment 73, control 122.
risk of no viral clearance, 73.0% lower, HR 0.27, p < 0.001, treatment 73, control 122, adjusted per study, inverted to make HR<1 favor treatment, viral shedding, multivariable, model 2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yan et al., 22 Mar 2023, retrospective, placebo-controlled, China, peer-reviewed, median age 74.0, 10 authors, study period 1 April, 2022 - 30 June, 2022.
Contact: shan_mou@shsmu.edu.cn, guleyi@aliyun.com, monsoon585@foxmail.com.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou
Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 . However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited. Methods: Data were collected from the patients admitted to a COVID-19 referral center in Shanghai, China. Patients were at least 18 years of age and had a baseline estimated glomerular filtration rate (eGFR) of <60 ml/min/1•73 m 2 . The primary endpoint was a composite of all-cause mortality, intensive care unit admission, or cardiovascular events. The secondary endpoint was viral shedding. Results: Among the 195 participants, 73 received nirmatrelvir/ritonavir. A lower risk of the primary endpoint was observed in nirmatrelvir/ritonavir recipients compared with non-recipients [adjusted HR 0.56 (95% CI: 0.32-0.96); p = 0.035]. Nirmatrelvir/ritonavir recipients experienced a shorter duration of viral shedding ; p < 0.001) and faster viral load clearance versus non-recipients. Among the nirmatrelvir/ritonavir users, earlier initiation of nirmatrelvir/ritonavir within 5 days since COVID-19 diagnosis was related with shorter viral shedding time ; p < 0.001) compared to late initiation. No patients reported serious adverse events during treatment. Conclusion: Our findings support the early initiation of nirmatrelvir/ritonavir for high-risk patients with impaired kidney function. This could improve patient outcomes and shorten the viral shedding period.
Ethics statement The studies involving human participants were reviewed and approved by Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. The ethics committee waived the requirement of written informed consent for participation. Author contributions JY, SM, and LG designed the study. JY, HC, and JW analyzed the data and revised the manuscript. JY and SM drafted and edited the final manuscript. All authors took part in collecting and verifying the Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Supplementary material The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1147980/ full#supplementary-material
References
Arbel, Wolff Sagy, Hoshen, Battat, Lavie et al., Nirmatrelvir use and severe covid-19 outcomes during the omicron surge, N. Engl. J. Med, doi:10.1056/NEJMoa2204919
Carlson, Nelveg-Kristensen, Freese Ballegaard, Feldt-Rasmussen, Hornum et al., Increased vulnerability to COVID-19 in chronic kidney disease, J. Intern Med, doi:10.1111/joim.13239
Christensen, Olsen, Long, Snehal, Davis et al., Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in houston, Texas, Am. J. Pathol, doi:10.1016/j.ajpath.2022.01.007
Dejnirattisai, Huo, Zhou, Zahradnik, Supasa et al., None
Gnanenthiran, Borghi, Burger, Caramelli, Charchar et al., Renin-angiotensin system inhibitors in patients with COVID-19: A metaanalysis of randomized controlled trials led by the international society of hypertension, J. Am. Heart Assoc, doi:10.1161/JAHA.122.026143
Graham, Daily briefing: Omicron coronavirus variant puts scientists on alert, Nature, doi:10.1038/d41586-021-03564-6
Hammond, Leister-Tebbe, Gardner, Abreu, Bao et al., Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-Associated hospitalization surveillance network (COVID-NET), Nat. Rev. Microbiol, doi:10.1093/cid/ciaa1012
Levey, Stevens, Schmid, Zhang, Castro et al., None
Lingscheid, Kinzig, Kruger, Muller, Bolke et al., Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with endstage renal disease on intermittent hemodialysis, Antimicrob. Agents Chemother
Lu, Zhang, Zhang, Ai, He et al., Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave, Emerg. Microbes Infect, doi:10.1080/22221751.2022.2109517
Mahase, Nahhas, Webster, Owen, The promising use of nanomolecular imprinted templates for improved SARS-CoV-2 detection, drug delivery and research, doi:10.1126/science.abl4784
Ozturk, Turgutalp, Arici, Odabas, Altiparmak et al., Mortality analysis of COVID-19 infection in chronic kidney disease, Frontiers in Pharmacology frontiersin
Qiao, Li, Zeng, Liu, Luo et al., SARS-CoV
Russo, Esposito, Taramasso, Magnasco, Saio et al., Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy, J. Nephrol, doi:10.1007/s40620-020-00875-1
Toussi, Neutel, Navarro, Preston, Shi et al., Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment, Clin. Pharmacol. Ther, doi:10.1002/cpt.2688
Wang, Peng, Ye, Li, Li et al., Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension, Front. Med, doi:10.1007/s11684-021-0850-9
Zhang, Wang, Ning, He, Wang, Protecting older people: A high priority during the COVID-19 pandemic, Lancet, doi:10.1016/S0140-6736(22)01530-6
Zhang, Zhang, Chen, Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic, Lancet, doi:10.1016/S0140-6736(22)00838-8
Zhang, Zhou ; Flythe, Assimon, Tugman, Chang et al., Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States, doi:10.1002/jmv.27491
Zhu, Xiao, Meng, Tang, Li et al., Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19, J. Nanobiotechnology, doi:10.1186/s12951-021-01148-0
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit